drugset / Trial / NCT06909474
Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This is a clincal trial initiated by investigator to evaluate the safety and efficacy of anti-CD5 CAR-NK in the treatment of patients with relapsed/refractory T-Cell hematologic malignancies.
Timeline
- Start
- 2025-03-27
- Primary completion
- 2027-03-31
- Completion
- 2028-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anti-CD5 CAR NK cells | Cell therapy | 1e+07 cells/kg | — |
| Subject | Anti-CD5 CAR NK cells | Cell therapy | 3e+07 cells/kg | — |
| Subject | Anti-CD5 CAR NK cells | Cell therapy | 5e+07 cells/kg | — |